Satellos Bioscience is developing small molecule therapeutics that target dystrophin-independent pathways to promote muscle regeneration in patients with Duchenne muscular dystrophy. Their approach aims to enhance muscle tissue growth and repair, addressing the critical need for effective treatments for this debilitating condition.
Funding
$57M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Duchenne muscular dystrophy (DMD) lacks effective treatments that promote muscle regeneration and repair, leading to progressive muscle degeneration and functional decline in affected individuals. Current therapies primarily address symptoms rather than targeting the underlying mechanisms of muscle wasting.
Solution
Satellos Bioscience is developing small molecule therapeutics designed to stimulate muscle regeneration in patients with DMD by targeting dystrophin-independent pathways. Their approach aims to modulate key signaling pathways within muscle tissue to enhance its capacity for growth and repair. The lead drug candidate is designed to promote muscle tissue growth and improve muscle function, offering a novel strategy for combating the progressive nature of DMD. By focusing on regenerative mechanisms, Satellos seeks to provide a disease-modifying treatment option that addresses the root cause of muscle degeneration in DMD.
Target Audience
The primary target audience includes patients diagnosed with Duchenne muscular dystrophy (DMD) and their families, as well as clinicians and researchers specializing in neuromuscular disorders.
Features
- Small molecule approach targeting dystrophin-independent pathways
- Designed to modulate muscle regeneration signaling
- Aims to enhance muscle tissue growth and repair
- SAT-3247: Lead drug candidate in Phase 1 clinical trials
- Potential to improve muscle function in DMD patients